In a first round of funding, Life Sciences Partners III, BiomedInvest AG and Novartis Venture Fund have invested EUR 7.2m in Okairos AG. The financing will enable the company to demonstrate proof of concept of its adenovirus-based technology in several indications.
Bid Equity began its social care and healthcare software buy-and-build strategy in 2017
Marfin has received a binding offer from CVC and granted the GP an exclusivity period until 6 November
Firms invested in the business in 2015 alongside management, acquiring it from Initiative & Finance
Healthtech company has raised $34.2m since being founded six years ago